[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577186":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":33,"centralContacts":37,"locations":43,"responsibleParty":228,"collaborators":33,"id":230,"slug":231,"hasResults":232,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":232,"sex":238,"minAge":239,"maxAge":33,"enrollmentInfo":240,"targetDuration":33,"studyType":243,"phases":244,"briefSummary":247,"conditions":248,"keywords":250,"overallStatus":59,"whyStopped":33,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":268},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8,14,19,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Module 1: AZD9793 Intravenous (IV) monotherapy Part A","EXPERIMENTAL","Module 1: AZD9793 Intravenous (IV) monotherapy Part A: Dose Escalation",[13],"Drug: AZD9793 Intravenous (IV) monotherapy",{"label":15,"type":10,"description":16,"interventionNames":17},"Module 2: AZD9793 Subcutaneous (SC) monotherapy Part A","Module 2: AZD9793 Subcutaneous (SC) monotherapy Part A: Dose Escalation",[18],"Drug: AZD9793 Subcutaneous (SC) monotherapy",{"label":20,"type":10,"description":21,"interventionNames":22},"Module 1: AZD9793 Intravenous (IV) monotherapy Part B","Module 1: AZD9793 Intravenous (IV) monotherapy Part B: Dose Expansion",[13],{"label":24,"type":10,"description":25,"interventionNames":26},"Module 2: AZD9793 Subcutaneous (SC) monotherapy Part B","Module 2: AZD9793 Subcutaneous (SC) monotherapy Part B: Dose Expansion",[18],[28,34],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","AZD9793 Intravenous (IV) monotherapy","T cell-engaging antibody that targets GPC3 on tumour cells",[9,20],null,{"type":29,"name":35,"description":31,"armGroupLabels":36,"otherNames":33},"AZD9793 Subcutaneous (SC) monotherapy",[15,24],[38],{"name":39,"role":40,"phone":41,"phoneExt":33,"email":42},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[44,58,67,77,86,95,104,113,123,131,139,147,152,160,170,178,187,192,202,210,220],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":33},"Research Site","WITHDRAWN","La Jolla","California","92093","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-117.2742,32.84727,{"lat":56,"lon":55},{"facility":45,"status":59,"city":60,"state":48,"zip":61,"country":50,"countryCode":51,"cosmosGeoPoint":62,"geoPoint":66,"contacts":33},"RECRUITING","Los Angeles","90089",{"type":53,"coordinates":63},[64,65],-118.24368,34.05223,{"lat":65,"lon":64},{"facility":45,"status":68,"city":69,"state":70,"zip":71,"country":50,"countryCode":51,"cosmosGeoPoint":72,"geoPoint":76,"contacts":33},"NOT_YET_RECRUITING","Baltimore","Maryland","21201",{"type":53,"coordinates":73},[74,75],-76.61219,39.29038,{"lat":75,"lon":74},{"facility":45,"status":68,"city":78,"state":79,"zip":80,"country":50,"countryCode":51,"cosmosGeoPoint":81,"geoPoint":85,"contacts":33},"Boston","Massachusetts","02114",{"type":53,"coordinates":82},[83,84],-71.05977,42.35843,{"lat":84,"lon":83},{"facility":45,"status":59,"city":87,"state":88,"zip":89,"country":50,"countryCode":51,"cosmosGeoPoint":90,"geoPoint":94,"contacts":33},"St Louis","Missouri","63108",{"type":53,"coordinates":91},[92,93],-90.19789,38.62727,{"lat":93,"lon":92},{"facility":45,"status":68,"city":96,"state":97,"zip":98,"country":50,"countryCode":51,"cosmosGeoPoint":99,"geoPoint":103,"contacts":33},"Hackensack","New Jersey","07601",{"type":53,"coordinates":100},[101,102],-74.04347,40.88593,{"lat":102,"lon":101},{"facility":45,"status":59,"city":105,"state":106,"zip":107,"country":50,"countryCode":51,"cosmosGeoPoint":108,"geoPoint":112,"contacts":33},"Houston","Texas","77030",{"type":53,"coordinates":109},[110,111],-95.36327,29.76328,{"lat":111,"lon":110},{"facility":45,"status":59,"city":114,"state":33,"zip":115,"country":116,"countryCode":117,"cosmosGeoPoint":118,"geoPoint":122,"contacts":33},"Chengdu","610041","China","CN",{"type":53,"coordinates":119},[120,121],104.06667,30.66667,{"lat":121,"lon":120},{"facility":45,"status":59,"city":124,"state":33,"zip":125,"country":116,"countryCode":117,"cosmosGeoPoint":126,"geoPoint":130,"contacts":33},"Guangzhou","510515",{"type":53,"coordinates":127},[128,129],113.25,23.11667,{"lat":129,"lon":128},{"facility":45,"status":68,"city":132,"state":33,"zip":133,"country":116,"countryCode":117,"cosmosGeoPoint":134,"geoPoint":138,"contacts":33},"Harbin","150049",{"type":53,"coordinates":135},[136,137],126.65,45.75,{"lat":137,"lon":136},{"facility":45,"status":59,"city":140,"state":33,"zip":141,"country":116,"countryCode":117,"cosmosGeoPoint":142,"geoPoint":146,"contacts":33},"Shanghai","201114",{"type":53,"coordinates":143},[144,145],121.45806,31.22222,{"lat":145,"lon":144},{"facility":45,"status":59,"city":148,"state":33,"zip":149,"country":150,"countryCode":151,"cosmosGeoPoint":33,"geoPoint":33,"contacts":33},"Pokfulam","999077","Hong Kong","HK",{"facility":45,"status":59,"city":153,"state":33,"zip":154,"country":150,"countryCode":151,"cosmosGeoPoint":155,"geoPoint":159,"contacts":33},"Shatin","000000",{"type":53,"coordinates":156},[157,158],114.18333,22.38333,{"lat":158,"lon":157},{"facility":45,"status":59,"city":161,"state":33,"zip":162,"country":163,"countryCode":164,"cosmosGeoPoint":165,"geoPoint":169,"contacts":33},"Kashiwa","277-8577","Japan","JP",{"type":53,"coordinates":166},[167,168],139.97732,35.86224,{"lat":168,"lon":167},{"facility":45,"status":59,"city":171,"state":33,"zip":172,"country":163,"countryCode":164,"cosmosGeoPoint":173,"geoPoint":177,"contacts":33},"Yokohama","241-8515",{"type":53,"coordinates":174},[175,176],139.65,35.43333,{"lat":176,"lon":175},{"facility":45,"status":68,"city":179,"state":33,"zip":180,"country":181,"countryCode":33,"cosmosGeoPoint":182,"geoPoint":186,"contacts":33},"Seoul","06351","South Korea",{"type":53,"coordinates":183},[184,185],126.9784,37.566,{"lat":185,"lon":184},{"facility":45,"status":59,"city":179,"state":33,"zip":188,"country":181,"countryCode":33,"cosmosGeoPoint":189,"geoPoint":191,"contacts":33},"5505",{"type":53,"coordinates":190},[184,185],{"lat":185,"lon":184},{"facility":45,"status":68,"city":193,"state":33,"zip":194,"country":195,"countryCode":196,"cosmosGeoPoint":197,"geoPoint":201,"contacts":33},"Barcelona","8035","Spain","ES",{"type":53,"coordinates":198},[199,200],2.15899,41.38879,{"lat":200,"lon":199},{"facility":45,"status":68,"city":203,"state":33,"zip":204,"country":195,"countryCode":196,"cosmosGeoPoint":205,"geoPoint":209,"contacts":33},"Pamplona","31005",{"type":53,"coordinates":206},[207,208],-1.64323,42.81687,{"lat":208,"lon":207},{"facility":45,"status":59,"city":211,"state":33,"zip":212,"country":213,"countryCode":214,"cosmosGeoPoint":215,"geoPoint":219,"contacts":33},"Taipei","10002","Taiwan","TW",{"type":53,"coordinates":216},[217,218],121.52639,25.05306,{"lat":218,"lon":217},{"facility":45,"status":59,"city":221,"state":33,"zip":222,"country":213,"countryCode":214,"cosmosGeoPoint":223,"geoPoint":227,"contacts":33},"Taoyuan","333",{"type":53,"coordinates":224},[225,226],121.29696,24.99368,{"lat":226,"lon":225},{"type":229,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR","100577186","phase-1-first-in-human-study-to-evaluate-azd9793-in-participants-with-advanced-or-metastatic-solid-tumours-100577186",false,"NCT06795022","First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours","A Modular Phase I\u002FII Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD9793, a T Cell-engaging Antibody Targeting Glypican-3 (GPC3) in Adult Participants With Advanced or Metastatic Solid Tumours (RHEA-1)","RHEA-1","Key Inclusion Criteria:\n\n* Age ≥ 18 at the time of signing the informed consent.\n* GPC3 positive tumour as determined by a central laboratory using an analytically validated IHC assay. Patients who previously received any therapy targeting GPC3 must undergo central laboratory GPC3 testing on tumour tissue collected after completion of the prior GPC3-targeted therapy.\n* Must have at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\n* Eastern Cooperative Oncology Group Performance status (ECOG PS): 0-1 at screening.\n* Predicted life expectancy of ≥ 12 weeks.\n* Adequate organ and bone marrow function measured within 28 days prior to first dose as defined by the protocol.\n* Contraceptive use by men or women should be consistent with local regulations, as defined by the protocol.\n* Confirmed advanced recurrent and\u002For metastatic and\u002For unresectable HCC, which is histopathologically proven based on the criteria established by the World Health Organization.\n* Barcelona Clinic Liver Cancer (BCLC) stage B (that is not eligible for locoregional therapy) or stage C.\n* Child-Pugh Score class A.\n* Previous therapy:\n\nPart A: Patients who have received at least one prior line of standard systemic therapy for HCC as per National Comprehensive Cancer Network or other local scientific guidelines and for which a clinical study is the best option for next treatment based on prior response and\u002For tolerability and\u002For patient\u002Finvestigator decision.\n\nPart B: Patients must not have received more than one prior line of systemic therapy in the advanced recurrent and\u002For metastatic setting.\n\nKey Exclusion Criteria:\n\n* Unresolved toxicity from prior anticancer therapy, including imAEs, of Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥ 2 except for vitiligo, peripheral neuropathy related to prior anti-cancer therapy, alopecia, endocrine disorders that are controlled with replacement hormone therapy and asymptomatic laboratory abnormalities.\n* Prior to enrolment, participation in another clinical study with an investigational product administered in the last 21 days or 5 half-lives whichever is shorter.\n* CAR-T cell therapy within the last 6 months prior to enrolment on this study.\n* Known allergy or hypersensitivity to AZD9793 or any of the excipients of the product as outlined in the IB.\n* Requires chronic immunosuppressive therapy (including steroids \\> 10 mg prednisone\u002Fday or equivalent).\n* Received radiation within 14 days prior to first dose of study treatment; palliative radiation to reduce the risk of tumour lysis syndrome (TLS) or CRS\u002Fneurotoxicity in participants with bulky disease is permitted.\n* Undergone a major surgical procedure within 14 days prior to first dose of study treatment days to allow adequate healing\n* Experienced unacceptable cytokine release syndrome (CRS) or Immune Effector Cell Associated Neurotoxicity (ICANS) following prior T cell engagers (TCE) or chimeric antigen receptor T (CAR-T) cell therapy.\n* Previous history of hemophagocytic lymphohistiocytosis (HLH) \u002F macrophage activation syndrome (MAS).\n* Active or prior documented autoimmune or inflammatory disorders within 3 years of start of treatment.\n* Cardiac conditions as defined by the protocol.\n* History of thromboembolic event within the past 3 months prior to the scheduled first dose of study intervention.\n* Central nervous system (CNS) metastases or CNS pathology, as defined by the protocol, within 3 months prior to consent.\n* Infectious disease including active human immunodeficiency virus (HIV), and uncontrolled active systemic fungal, bacterial or other infection.\n* Known fibrolamellar HCC, sarcomatoid HCC, or combined hepatocellular malignant cholangiocarcinoma.","ALL","18 Years",{"count":241,"type":242},304,"ESTIMATED","INTERVENTIONAL",[245,246],"PHASE1","PHASE2","This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours which are GPC3+.",[249],"Hepatocellular Carcinoma",[251,252,253,254,255,256,257,258],"Glypican-3","GPC3","GPC3+ tumours","T cell-engaging antibody","TCE","AZD9793","Solid tumours","HCC","2026-08-12",{"date":261,"type":262},"2026-08-13","ACTUAL",{"date":264,"type":262},"2025-03-27",{"date":266,"type":242},"2028-06-30",{"name":5,"class":6},21]